Date | Insider | Price | Amount |
---|---|---|---|
6-21-2021 Insider Buy |
Mark J. Alles Director |
$81.34 CAGR » |
$162,680.00 2,000 shares |
5-21-2020 Insider Buy |
Plc Glaxosmithkline Director |
$60.00 CAGR » |
$4,999,980.00 83,333 shares |
5-21-2020 Insider Buy |
Athena Countouriotis President & CEO |
$60.00 CAGR » |
$249,960.00 4,166 shares |
5-21-2020 Insider Buy |
Simeon George Director |
$60.00 CAGR » |
$4,999,980.00 83,333 shares |
9-10-2019 Insider Buy |
Plc Glaxosmithkline Director |
$45.00 CAGR » |
$7,999,965.00 177,777 shares |
9-10-2019 Insider Buy |
Yi Larson EVP & Chief Financial Officer |
$45.00 CAGR » |
$99,990.00 2,222 shares |
9-10-2019 Insider Buy |
Plc Glaxosmithkline Director |
$45.00 CAGR » |
$7,999,965.00 177,777 shares |
9-10-2019 Insider Buy |
Simeon George Director |
$45.00 CAGR » |
$7,999,965.00 177,777 shares |
9-10-2019 Insider Buy |
Athena Countouriotis President & CEO |
$45.00 CAGR » |
$450,000.00 10,000 shares |
4-22-2019 Insider Buy |
Asset Management, LP Cormorant >10% Owner |
$18.00 CAGR » |
$7,200,000.00 400,000 shares |
4-22-2019 Insider Buy |
Plc Glaxosmithkline Director and >10% Owner |
$18.00 CAGR » |
$5,850,000.00 325,000 shares |
4-22-2019 Insider Buy |
ORBIMED ADVISORS LLC Director |
$18.00 CAGR » |
$6,480,000.00 360,000 shares |
4-22-2019 Insider Buy |
Athena Countouriotis President & CEO |
$18.00 CAGR » |
$216,000.00 12,000 shares |
4-22-2019 Insider Buy |
Brian Lee Baker VP of Finance and Admin. |
$18.00 CAGR » |
$50,400.00 2,800 shares |
4-22-2019 Insider Buy |
Simeon George Director |
$18.00 CAGR » |
$5,850,000.00 325,000 shares |
4-22-2019 Insider Buy |
Carl L. Gordon Director |
$18.00 CAGR » |
$6,480,000.00 360,000 shares |
4-22-2019 Insider Buy |
Hongbo Lu Director |
$18.00 CAGR » |
$1,080,000.00 60,000 shares |
Also See: Institutional Holders of TPTX
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 06/22/2021 | |
End date: | 09/07/2022 | |
Start price/share: | $80.12 | |
End price/share: | $76.01 | |
Dividends collected/share: | $0.00 | |
Total return: | -5.13% | |
Average Annual Total Return: | -4.26% | |
Starting investment: | $10,000.00 | |
Ending investment: | $9,486.48 | |
Years: | 1.21 |
Turning Point Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Turning Point Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding TPTX
Free TPTX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |